Zoledronic acid is an established agent used in the management of metastatic bone disease. The administration of zoledronic acid improves overall survival (OS) of lung cancer patients with bone metastases receiving chemotherapy. However, it is currently unknown whether zoledronic acid-induced fever is associated with OS. The purpose of this study was to examine the association between zoledronic acid-induced fever and prognosis in lung cancer patients with bone metastases. We retrospectively analyzed 98 lung cancer patients with bone metastases who had received zoledronic acid. The end point outcome measure was OS. Multivariate analyses were used to estimate the hazard ratio (HR) for OS due to fever after adjusting for covariates. In multivariate analysis, white blood cell (WBC) count, lac...
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2rnZLk5
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
A host of new therapies are now available for treating patients with chronic lymphocytic leukemia (CLL) in both the upfront and relapsed or ...
-
Related Articles Middle ear adenomatous neuroendocrine tumors: a 25-year experience at MD Anderson Cancer Center. Virchows Arch. 2017...
-
Abstract Background The role of thymectomy in the treatment of juvenile myasthenia gravis (JMG) is poorly defined. The objective of this...
-
Biomarker testing is recommended for all patients diagnosed with non–small cell lung cancer. At a minimum, testing should include the mutati...
-
Early Antarctic ice age dynamics Antarctica. Image courtesy of Wikimedia Commons/Dave Pape. The extent of Antarctic ice sheets oscillated wi...
-
http://ift.tt/2rdV14q
-
American Thyroid Resarch Grant to Nikita Pozdeyev, MD, PhD, University of Colorado Newswise (press release) The 2016 Research Grant h...
-
We thank Liu et al. (1) for their comments on our paper (2). The first point of Liu et al. (1) is that the Lake Dali Early Holocene highstan...
-
In the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer, among adjuvant radiotherapy options for whole-brea...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου